Mammary ductal dysplasia is a phenotype observed in precancerous lesions and earlystage breast cancer. However, the mechanism of dysplasia formation remains elusive.
Introduction
During breast tumorigenesis, mammary ductal dysplasia is observed in precancerous lesions and early-stage breast cancers. Mammary ductal dysplasia exhibits a loss of the biphasic mammary epithelial and myoepithelial pattern, an abnormal nucleus, epithelial cell expansion, a disruption in the myoepithelial cell layer and/or mammary epithelial cell invasion to fibrous stroma, whereas a normal mammary duct maintains cell polarization, the biphasic pattern and the smooth luminal surface of the mammary epithelial cell layer.
Given that dysplasia can progress to malignant neoplasms (1) (2) (3) , elusicating the mechanism of dysplasia formation will contribute to the prevention of breast tumorigenesis.
Previous studies have established various breast cancer mouse models by genetic engineering. For example, the mammary gland-specific expression of c-neu (Her2/ErbB2), polyoma middle T antigen and Wnt-1 causes breast cancer (4) (5) (6) . Mice with a mutation in Tp53, a tumor suppressor gene, also developed breast cancer (7) . Although these models have provided knowledge about breast cancer, particularly at an advanced stage, they have not been primarily used for studies on mammary ductal dysplasia observed in precancerous lesions and early-stage breast cancers. Previous dysplasia studies in mice used radiation in Atm heterozygous mice (8) , and overexpression of constitutively activated SMO (9) and of the oncogene NSD3 (10) . Because studies using genetically engineered mice have been designed to examine phenotypes specifically caused by the functions of their target genes, these models are not suitable to elucidate the mechanism by which mammary ductal dysplasia is naturally formed. To understand such a mechanism of dysplasia formation, a mouse model that form dysplasia by physiological factor(s) is required.
Estrogen, a female hormone, promotes the development of the normal mammary dust and the proliferation of breast cancer (reviews, (11) (12) (13) (14) ). There are a number of studies on the function of estrogen in breast cancer (reviews, (11, (13) (14) (15) (16) ).
Although estrogen is thought to be involved in breast tumorigenesis in epidemiologic studies (17) , and combination of radiation and E2 treatment transformed normal mammary cells in vitro (18) , there is no experimental evidence showing that estrogen receptor α (ERα)-mediated estrogen signaling induces mammary dysplasia from normal mammary epithelial cells in vivo.
Estrogen regulates gene expression via the activation of ERα. In mammary glands, ERα is expressed mainly in mammary epithelial cells. Although there are various functional models of ERα action, in the classical mechanism of ERα, estrogen-bound ERα forms a dimer, localizes in the nucleus, and binds to its DNA binding site to regulate gene expression (reviews, (12, 15, (19) (20) (21) ). Thus far, various ERα-regulated genes have been identified (13, 14, 16) ; these include growth regulating estrogen receptor binding 1 (GREB1), trefoil factor 1 (TFF1, pS2) (22, 23) . During ERα-mediated gene regulation, a DNA double-strand break is made at the promoter of a target gene to promote its expression (24, 25) . Whether ERα-mediated gene regulation with a DNA double-strand break is involved in dysplasia formation remains unclear. In this study, we successfully established a novel dysplasia model system and investigate the mechanism of dysplasia formation.
Results

Enhancement of ERα-mediated estrogen signaling causes mammary ductal dysplasia.
To investigate E2-induced DNA damage in vitro, We treated an ERα-positive breast cancer cell line, MCF-7, with or without estradiol (E2), the most active form of estrogen, and investigated DNA double-strand breaks ( Fig. S1A ). We counted the number of the signals of phosphorylated-histone H2AX (gamma-H2AX, gH2AX), a marker of DNA double-strand breaks. The number of gH2AX signals was increased by E2 treatment and reduced by cotreatment with fulvestrant, an estrogen receptor inhibitor ( Fig. S1A ), indicating that E2 treatment causes DNA double-strand breaks via its receptor. An inhibitor of DNA-dependent protein kinase (DNA-PK), NU-7441, inhibits nonhomologous end joining repair, one of the repair mechanisms of DNA double-strand breaks (26) . NU-7441 treatment did not change the number of gH2AX signals after 2 h treatment ( Fig. S1A) , indicating that the loss of DNA-PK function does not change E2generated DNA damage in our conditions.
To determine whether estrogen-induced DNA double-strand breaks are involved in the regulation of the downstream genes of estrogen signaling, we reduced the capacity of nonhomologous end joining by knocking down PRKDC, which encodes the catalytic subunit of DNA-PK (27) . Cells were washed with medium in the absence of E2 after E2 treatment to analyze repair capacity. No increase in the number of gH2AX signals was observed in control cells ( Fig. 1A) , indicating that cells repaired E2-induced DNA double-strand breaks during 2 h of washing under our conditions. However, the gH2AX signal was retained after washing in PRKDC knockdown cells ( Fig. 1A, S1B ), suggesting that the loss of DNA-PK function delays the repair of E2-induced DNA double-strand breaks. Longer-retaining DNA breaks are believed to be involved in transcriptional regulation, at least in specific cases (28) . To investigate the expression of ERα downstream genes under our conditions, mRNA levels were quantified (Fig. 1B) . The expression of GREB1 and TFF1 tended to increase following PRKDC knockdown, although there was no significant difference. These results suggest that a reduction in the repair capacity for DNA double-strand breaks enhances the expression of some ERαregulated genes in response to E2 stimulation.
We injected E2 (6 μg/mouse) intraperitoneally into scid mice with a genetic defect in DNA-PKcs function (29, 30) . The serum concentration of E2 was transiently increased and reduced to the background level after 6 h in both wild-type and scid mice ( Fig. S1C ). The results of gH2AX staining showed an increased number of gH2AXpositive mammary epithelial cells (Fig. 1C ). As expected, scid mice showed a larger number of gH2AX-positive cells than wild-type mice.
To investigate whether long term-E2 administration could cause an abnormality in the mammary gland, we performed consecutive daily injections of E2 for 30 days. No significant change in body weights was observed after 30 days of injection ( Fig. S2A ).
Hematoxylin and eosin (H&E) staining showed normal mammary ducts in both wild-type and scid mice at day 7 ( Fig. S2B ). At day 30, whereas E2-injected wild-type (WT+E2) and phosphate-buffered saline (PBS)-injected scid (scid+PBS) mice exhibited normal mammary ducts ( Fig. 1D ), dysplasia formation (i.e., increased cell number, loss of biphasic mammary epithelial and myoepithelial patterns, and epithelial cell expansion to outside of a duct) was observed in E2-injected scid mice (scid+E2) ( Fig. 1D,S2C) .
Because human breast cancer shows a disruption in the myoepithelial layer (3), we immunostained cells for the myoepithelial cell markers cytokeratin 5 (CK5) ( Fig. 1E ) and p63 ( Fig. S2D ). We observed a disruption in the myoepithelial layers in mammary ducts with dysplasia. To determine whether mammary epithelial cells of the ducts with dysplasia invaded to the outside of myoepithelial layer, co-immunostaining of CK5 and a mammary epithelial cell marker CK8 was performed (Fig. 1F ). The results revealed mammary ducts with increased mammary epithelial cell numbers and loss of the biphasic pattern ( Fig. 1F intraductal) and mammary ducts with epithelial cells in the extraductal region with a disruption in the CK5 cell layer ( Fig. 1F extraductal) in scid+E2. Since terminal end buds are epithelial cell-rich regions that can be identified as a duct with no fibrous stroma region (31) and since it is difficult to distinguish dysplasia from normal terminal end bud, these were excluded in the analyses. We analyzed the frequency of dysplasia formation and observed significant increases in both intraductal and extraductal expansion ( Fig. 1F graph) . A duct with both intraductal and extraductal expansion was counted as a duct with extraductal expansion. These results suggest that repetitive E2 administration induces mammary ductal dysplasia in mice that are susceptible to estrogen, such as scid mice. Coadministration with the estrogen receptor inhibitor (scid+E2+Fulv.) showed no increase in the frequency of dysplasia, suggesting that the suppression of estrogen receptor function may prevent dysplasia formation.
We coadministered NU-7441, a DNA-PK inhibitor, and E2 to two wild-type strains, C.B17/Icr and C57BL/6J. C.B17/Icr is the parental strain of scid mice. C57BL/6J is a commonly used strain. At day 30, we observed an increase in dysplasia formation in NU-7441+E2 mice compared to NU-7441+PBS mice in both strains (Fig. S3 ). This result indicates that E2 administration can induce mammary ductal dysplasia not only in scid mice but also in various mouse backgrounds.
Progesterone inhibits E2-induced dysplasia formation.
Progesterone (PG), a female hormone, alters ERα function in malignant breast cancer through progesterone receptor (PGR), and the administration of PG reduced E2dependent tumor growth in mouse xenograft experiments with MCF-7 cells (32). To determine whether PG-activated PGR inhibits E2-induced DNA double-strand breaks in MCF-7 cells, we performed combination treatment of E2 and PG with or without PGR knockdown ( Fig. 2A, B ). The number of gH2AX signals was increased by E2 treatment but not in the combination of E2 and PG (Fig. 2B ). In PGR knocked-down cells, the combination treatment of E2 and PG resulted in increased number of gH2AX signals, similar to E2 treatment, suggesting that PGR prevents E2-induced DNA double-strand breaks.
The function of PG in dysplasia formation in vivo remain elusive. To this end, we coinjected E2 and PG into our dysplasia model system. In scid mice, the administration of E2 alone caused dysplasia formation, and the coadministration of E2 and PG prevented dysplasia formation ( Fig. 2C ). Double immunostaining of CK5 and CK8 showed that PG administration prevented extraductal expansion (Fig. 2D ). The quantification of intraductal and extraductal expansion showed that PG reduced the frequencies of these abnormalities (Fig. 2D ). These results suggest that PG has a protective effect for E2-induced DNA damage and dysplasia formation.
Estrogen promotes mammary epithelial cell proliferation.
Because the number of CK8-positive cells was likely increased in scid+E2 mice (Fig. 1F ), we investigated cell proliferation by immunostaining for PCNA, an S-phase marker, and Ki-67, a proliferation marker, at day 30 (Fig. 3A, B ). The results of immunostaining showed that the ratio of proliferating mammary epithelial cells was increased in scid+E2 mice, and this increase was inhibited by the ERα inhibitor (scid+E2+Fulv.). An increased number of proliferating cells was also observed at day 7 ( Fig. 3C ). To investigate organ level changes, we visualized mammary ducts by Carmine Alum-staining ( Fig. 3D ). The mammary glands of scid+E2 mice were more densely distributed than those of the control mice and exhibited more small small branches. We quantified the number of branches and found that it was increased in scid+E2. These results suggest that E2 administration induces cell proliferation in the mammary glands of scid mouse.
Isoflavones prevent E2-induced dysplasia formation.
Our dysplasia model system can be utilized to study breast cancer prevention. Isoflavones are flavonoids and are rich in soybean. Epidemiological studies have suggested that isoflavones have a protective effect against breast cancer (33) . Genistein, an isoflavone, inhibited breast cancer cell growth (34) . On the other hand, a study using breast cancer cells showed that genistein promoted tumor growth (35) . Therefore, the effect of isoflavones in breast cancer is still controversial. To address this issue, we investigated the effect of isoflavones in our dysplasia model system. We used two isoflavones, (S)equol and genistein. When E2-induced DNA double-strand breaks were analyzed, both isoflavones reduced E2-induced DNA damage ( Fig. 4A ), suggesting that isoflavones have a potential to inhibit E2 function.
The coadministration of E2 and isoflavones reduced cell proliferation of mammary epithelial cells in vivo (Fig. 4B, S4A ). The number of branches was reduced by isoflavones ( Fig. 4C,S4B ). These results suggest that isoflavones were effective at preventing E2-induced cell proliferation. H&E staining showed that most of the mammary ducts of mice coadministered E2 and isoflavones had normal ductal structures and retained the biphasic mammary epithelial and myoepithelial pattern (Fig. 4D ). The results of CK5 and CK8 immunostaining showed that the ratio of intraductal and extraductal expansion was reduced by isoflavone administration (Fig. 4E) . These results indicate that isoflavones have the potential to prevent E2-induced dysplasia formation.
Discussion
We demonstrated E2-induced mammary ductal dysplasia in mice, providing direct evidence that estrogen causes mammary ductal dysplasia. This study showed that reduced DNA repair capacity enhances estrogen signaling, which promotes dysplasia formation.
In human, long-term estrogen exposure has the potential to cause breast cancer (17) . On the other hand, DNA repair capacity is not maintained throughout life (36, 37) . In the breast, human mammary epithelial cells from aged donors were more sensitive to mammography-induced DNA damage than the cells from young donors (38) . Mammary epithelial cells from older women showed a delay of DNA double strand break repair, compared to those from younger women (39) . Mutations in genes related to the DNA damage response/repair lead to the risk of developing breast cancer (40, 41) . Our dysplasia-inducing model (i.e., 30-day E2 injection in mice with reduced DNA repair capacity) may mimic some of the situations of human breast tissue that are susceptible to mammary ductal dysplasia. Although our dysplasia model uses an excess amount of E2 and mice with reduced DNA repair capacity, it will be useful to investigate the mechanism of dysplasia formation and to develop a method for dysplasia prevention. We showed dysplasia formation in wild-type strains by coadministration of the DNA-PK inhibitor and E2.
These results indicate that our dysplasia model system can be utilized in various strains and genetically engineered mouse models, such as Tp53-knockout mice. For the breast cancer prevention study, we showed the first experimental evidence that isoflavones inhibited E2-induced dysplasia formation. In future, this dysplasia induction model system may contribute to the understanding of breast cancer tumorigenesis and to the development of breast cancer prevention. 
Methods
Cell
Loss of function study
Mouse experiments
Female C.B17/Icr wildtype (C.B17/Icr-scidJcl +/+) and scid (C.B17/Icr-scidJcl scid/scid) mice were purchased from CLEA Japan (Tokyo, Japan) (6~8-week-old). Six-week-old female C57BL/6J mice were purchased from Japan SLC (Hamamatsu, Japan).
Intraperitoneal injection was performed with 30G needle in the morning. Injected 
Immunostaining in mammary gland
For cryo-section, isolated mammary gland was fixed with 4% PFA in PBS shortly (4 ℃, For DAB colorimetric detection, after secondary antibody reaction, specimen was washed with PBS 3 times and incubated with ABC kit (Vector, PK-6101 Fig. 1 Estrogen administration induces mammary ductal dysplasia in scid mice.
Figures
A, DNA double-strand breaks were detected in MCF-7 cells. PRKDC was knocked-down.
Gamma-H2AX was immunostained. Numbers of gH2AX foci per cell were graphed 
